^
    Apply
    Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (IOV-CLL-01) (NCT04155710)
    Phase 1/2
    Iovance Biotherapeutics, Inc.
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    02/19/2020
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • IL2
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    IOV-2001